-
J&J’s Actelion acquisition expected to close this quarter
NEW BRUNSWICK, N.J. — Johnson & Johnson confirmed Tuesday during its 2017 fiscal first-quarter earnings report that it expects its $30 billion acquisition of Actelion to close this quarter.
“The public tender offer for Actelion has been declared successful based on the number of shares tendered and regulatory approval has been obtained in six of seven jurisdictions in which the company filed for such approval, with antitrust approval from the European Commission pending.”
-
FDA approves Genentech’s bladder cancer drug
WASHINGTON — The Food and Drug Administration granted accelerated approval to Genentech’s Tecentriq (atezolizumab) for the treatment of people with locally advanced or metastatic urothelial carcinoma (mUC) who are not eligible for cisplatin chemotherapy. Tecentriq was previously approved for people with locally advanced or mUC who have disease progression during or following any platinum-containing chemotherapy, or within 12 months of receiving chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant).